Table 1.
Ongoing trials with chloroquine (CQ) and hydroxychloroquine (HCQ) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection/COVID-19 as of 19 April 2020.
| ClinicalTrials.gov IDa | Title | No. of participants | Phase |
|---|---|---|---|
| NCT04351724 | Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) | 500 | 3 |
| NCT04321278 | Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 virus (Coalition Covid-19 Brasil II) | 440 | 3 |
| NCT04303299 | Various combination of protease inhibitors, oseltamivir, favipiravir, and hydroxychloroquine for treatment of COVID-19: a randomized control trial | 320 | 3 |
| NCT04325893 | Hydroxychloroquine versus placebo in COVID-19 patients at risk for severe disease | 1300 | 3 |
| NCT04316377 | Norwegian coronavirus disease 2019 study | 202 | 4 |
| NCT04330144 | Hydroxychloroquine as post exposure prophylaxis for SARS-CoV-2 (HOPE Trial) | 2486 | 3 |
| NCT04342221 | Hydroxychloroquine for COVID-19 | 220 | 3 |
| NCT04340544 | Hydroxychloroquine for the treatment of mild COVID-19 disease | 2700 | 3 |
| NCT04346329 | Immune monitoring of prophylactic effect of hydroxychloroquine in healthcare providers highly exposed to COVID-19 | 86 | 3 |
| NCT04341727 | Hydroxychloroquine, hydroxychloroquine, azithromycin in the treatment of SARS CoV-2 infection | 500 | 3 |
| NCT04346667 | Post-exposure prophylaxis for asymptomatic SARS-CoV-2 COVID-19 patients with chloroquine compounds | 400 | 4 |
| NCT04351191 | Prophylaxis of exposed COVID-19 individuals with mild symptoms using chloroquine compounds | 400 | 4 |
| NCT04333732 | CROWN CORONATION: chloroquine repurposing to health workers for novel coronavirus mitigation | 55 000 | 3 |
a
At ClinicalTrials.gov (https://www.clinicaltrials.gov/).